Abstract
INTRODUCTION
Heart failure (HF) affects an estimated 5.8 million people in the United States and contributes to over 300000 deaths every year [1, 2] . It is the most common cause of hospital admission and readmission in people greater than 65 years of age, annually accounting for over 2.4 million hospitalizations [2, 3] and $39 billion in healthcare costs [1, 4] . Although most patients respond favorably to standard medical treatment, a considerable number of patients progress to end-stage HF refractory to medical therapy [5] . Currently, orthotopic heart transplant (OHT) is the gold standard therapy for these patients [6] [7] [8] , but the number of donor hearts available for transplantation is far fewer than the number of patients on the transplant list. For this reason, left ventricular assist devices (LVADs), a class of electromechanical devices used for cardiac circulatory support, are increasingly being used to bridge patients to cardiac transplantation [5] . The REMATCH trial in 2001 showed significant mor tality reductions in patients placed on a pulsatile-flow LVAD compared to standard medical treatment [9] . Several subsequent studies since have confirmed the survival benefit of both the older pulsatile and newer continuous flow LVADs [10] [11] [12] [13] . Although LVADs have substantially reduced mortality in end-stage HF patients, the absolute mortality rates still remain high. A large portion of this mortality is attributable to complications and other occurrences during the patient's stay in the hospital [14] .
In-hospital mortality rates as high as 27% have been reported in patients after LVAD surgery [15] [16] [17] [18] . As the rate of LVAD implantation in the United States continues to increase [19] [20] [21] [22] , effective recommendations for the in-hospital management of LVAD implantation are needed. Although the majority of cardiac transplants performed after LVAD implantation occur after a patient has been discharged from hospital, there is an important cohort of patients who cannot be discharged from hospital post-LVAD implant due to severe right ventricular failure, arrhythmias refractory to oral therapy, and infectious complications. Patients bridged to OHT with a LVAD achieve similar survival rates as patients who undergo direct heart transplant [14] , but there is little data to guide clinicians on the optimal timing of same-admission OHT after LVAD implantation. Though patients receiving LVADs may be considered for OHT while still inpatients, some have argued that performing OHT early after LVAD placement poses an increased risk of morbidity and mortality to patients.
Past studies on the appropriate use and outcomes of LVADs have been mostly limited to institutional experience and case series of select populations. While such descriptive investigations are useful, they are often limited by small sample size and variation between institutions and comparison groups. We used the Nationwide Inpatient Sample (NIS), the largest national database of hospitalizations in the United States with data from over 36 million hospitalizations, to assess the optimal timing of OHT after LVAD implantation. The NIS dataset complements the UNOS database and INTERMACS dataset with additional information on patient comorbidities, additional same-hospitalization procedures, hospital and center characteristics, and markers of patient's socioeconomic status including insurance provider and regional income quartiles. In addition, the NIS dataset contains data on both LVAD and inpatient OHT, which are not simultaneously available in the UNOS or INTERMACS databases.
We analyzed a patient cohort who had OHT performed during the same admission after LVAD implantation. We hypothesized that early OHT after LVAD implantation would be associated with higher mortality than late OHT, and that the hospital length of stay (LOS) after early OHT would be less than LOS after late OHT.
MATERIALS AND METHODS

Data source
The 
Study design and cohorts
This was a retrospective cross-sectional study using the NIS between 1998 and 2011. We identified all hospitalizations from 1998 to 2011 of patients 18 years of age or older who underwent LVAD implantation and for whom the hospital day of each procedure was available. Procedures during the hospitalization in addition to LVAD placement, including OHT, extracorporeal membrane oxygenation, intubation, hemodialysis, invasive hemodynamic monitoring, and surgical revision were identified by associated ICD9 codes (Supplementary Table 1 ). Additionally, hospital mortality and perioperative morbidity such as post-operative infections, cardiopulmonary complications, and hemorrhagic complications requiring endoscopy were identified.
Statistical analysis
The statistical methods of this study were reviewed by Dr. 
RESULTS
Baseline patient characteristics
We identified 2200 patients greater than 18 years of age between 1998 and 2011 who underwent LVAD implantation and for whom hospital day of procedure was listed (66.4% of all LVAD patients in the NIS database 1998-2011). Comparison of baseline characteristics between this study sample and all LVAD patients in the NIS 19982011 database confirmed that our study sample is representative of the entire patient population. The two groups were well matched based on age, sex, household income, prevalence of comorbidities, length of stay, and number of comorbidities, however there were more patients without documented race in the overall group (Supplementary Table 2 ). The mean age of all patients was 53.4 years (SD = 13.7, range = 18-92 years). Baseline patient demographics, patient comorbidities, and hospital characteristics were well matched between LVAD patients with and without same-admission OHT (Table 1) . Most LVAD implantations were performed in large (87.8%), urban (99.1%), teaching hospitals (92.4%). The most common comorbidities were diabetes (17.8%), disorders of lipid metabolism (14.1%), hypertension (13.7%), history of or current use of tobacco (6.5%), and BMI ≥ 30 kg/m 2 (4.4%). The mean day of LVAD implantation was 9.4 d (SD = 12.5 d) into the hospitalization. The overall inhospital mortality rate was 26.8%, with respiratory failure, cardiac dysrhythmias, right HF, and renal failure among the most frequent in-hospital complications immediately following LVAD implantation (Table 2) . Our dataset includes patients from both the pulsatileflow era (19982005) and the continuousflow era (2006 2011) of mechanical support (Table 3 ). Comparing the two eras, there was significantly less mortality in the continuous-flow era compared to the pulsatile-flow era (20.4% vs 43.0%; P < 0.001) even as patients were older (55.4 years vs 53.2 years; P < 0.001) and suffering more comorbid diagnoses (13.5 vs 10.6; P < 0.001). During the continuousflow era, fewer patients received OHT during the same admission as LVAD implantation (3.8% vs 17.3%; P < 0.001), and mechanical support was more frequently initiated in large (88.8% vs 85.1%; P = 0.002), teaching (94.4% vs 87.1%; P < 0.001) institutions. Median household income quartile and race distribution also were different between the two eras, although there was no difference in gender ratio of patients.
Timing of post-LVAD OHT
Of the patients who underwent LVAD implantation, 164 (7.5%) also underwent OHT during the same admission. OHT occurred a median of 32 d (IQR 7.75-66 d) after LVAD implantation. Patients who underwent OHT at least 8 d after LVAD implantation experienced significantly lower mortality compared to patients who underwent OHT earlier (26.8% vs 12.2%; P = 0.048; Table 1 and Figure  1 ). Baseline patient demographics, patient comorbidities, and hospital characteristics were similar between the early and late OHT groups. LVAD patients who underwent late OHT also had lower mortality compared to LVAD patients who were not transplanted (12.2% vs 27.0%; P < 0.001). However, LVAD patients who underwent early Gulati G et al . OHT timing after LVAD placement trend with delayed OHT post-LVAD was observed in both the pulsatile-flow (13.8% vs 36.4%; P = 0.081) transplant did not experience a similar mortality benefit (26.8% vs 27.0%; P = 0.946). The reduced mortality LVAD transplant can lead to superior outcomes is consistent with the excellent long term outcomes of BTT mechanical support, pushing some groups to question the justification of elective IA status [23] . Our study, using a large national database, solidifies and extends previous findings that early transplantation after initiation of BTT mechanical support is associated with worse outcomes. In the pulsatileflow era of LVAD, John et al [24] (2010) had shown that cardiac transplants done less than 6 wk after LVAD confer higher mortality risk in patients, and Gammie et al [25] (2003) and Ashton et al [26] (1996) have similarly reported optimal timing to be 2 wk after LVAD implantation. With the advantage of procedural timing data of patients who underwent same admission LVAD implantation and transplant, we add to those findings by showing there is an increased mortality associated with early same-admission transplant after LVAD in the continuous flow era.
During the study period between 1998 and 2011, there was a significant increase in the number of LVAD implantations, but patient characteristics of this population -including timing of LVAD, usage of invasive hemodynamic monitoring, and timing of post-LVAD OHT -has remained relatively unchanged. Our sample patient population is representative of LVAD patients studied in other databases with regards to age, gender, race, and other demographic characteristics and also mortality trends between the pulsatile and continuousflow eras. Without randomized control trials to better characterize the optimal management and timing of transplant after LVAD, our study describes representative clinical practice and trends in outcomes associated with changing practice patterns.
Our study has a few limitations. First, the NIS is a deidentified administrative database dependent on the appropriate coding of individual ICD-9-CM codes. Studies using such databases are susceptible to errors related to coding such as undercoding complications or variation in the application of diagnostic codes. This database also lacks many details available in registries, and unmeasured confounders cannot be excluded. Additionally, the NIS only captures events during the hospitalization, so complications and adverse events after discharge are not recorded. This limitation is counterbalanced by the larger sample size relative to other studies and the absence of reporting bias as compared to studies relying upon the and continuousflow eras (9.3% vs 15.8%; P = 0.672), although due to small sample numbers in each subgroup, the differences were not statistically significant ( Table  2 ). Multivariate linear model also confirmed the strong association between early OHT after LVAD and inhospital mortality, independent of patient age, LVAD era, comorbidities, and demographics (Table 4) .
Comparing the quartiles of post-LVAD OHT transplant times, there was no statistically significant difference in posttransplant length of stay (23.8 ± 21.4 d for the first quartile, 21.7 ± 15.8 d for the second quartile, 27.6 ± 37.1 d for the third quartile, 27.1 ± 22.8 d for the fourth quartile; P = 0.6571 comparing first quartile to other quartiles; Table 1 ). However, as expected, patients who waited longer after LVAD implantation for OHT had longer overall hospital stays (39.3 ± 33.2 d for the first quartile, 48.87 ± 25.6 d for the second quartile, 85.8 ± 40.1 d for the third quartile, 151.2 ± 52.6 d for the fourth quartile; P < 0.001 comparing first quartile to other quartiles; Table 1 ).
DISCUSSION
Our study addresses the difficult question of timing of same-admission OHT after LVAD implantation. Using the inpatient data on procedure timing from the NIS 1998-2011, we show that mortality risk significantly decreases in patients who undergo OHT at least 8 d after LVAD implantation. We also report that posttransplant length of stay is independent of the timing of OHT after LVAD.
For patients who receive an LVAD for bridge to transplant therapy (BTT), the optimal timing of post-LVAD OHT is controversial. The need for clinical stability and time to recover from major surgery is counterbalanced by the risk of LVAD complications and the formation of adhesions and scarring, particularly when OHT is considered early after LVAD implantation.
The high failure rate of the early, pulsatile-flow LVADs had in part led to the initial 1999 UNOS allocation algorithm giving LVAD patients 30 d of IA status on the transplant list. The elective nature of the 30-d IA status allows for optimization of management prior to transplant and suggests the time period immediately post-mechanical support is often not the optimal time for transplant. Our data showing that delaying post- It is important to note that our cohort only assessed outcomes of OHT after LVAD placement in hospitalized patients. This represents a minority of patients (7.5%) in practice, as most institutions prefer to wait 2-3 mo after LVAD implantation to list patients for cardiac transplantation. Nevertheless, there will continue to be patients in the future who receive same-admission OHT after LVAD implantation, and our study provides meaningful guidelines on the timing of such OHT.
In conclusion, our analysis suggests that delayed same-admission OHT after LVAD implantation decreases mortality risk without increasing post-transplant length of stay, and, therefore, may be the preferred option in such a clinical setting. This new understanding of the optimal timing of same-admission OHT after LVAD implantation can greatly improve patient outcomes, although prospective data will be needed to enhance the validity of our findings.
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Background
Heart failure (HF) affects an estimated 5.8 million people in the United States and contributes to over 300000 deaths every year. Although most patients respond favorably to standard medical treatment, a considerable number of patients progress to end-stage HF refractory to medical therapy. Orthotopic heart transplant (OHT) is currently the gold standard therapy for these patients, but the number of donor hearts available for transplantation is far fewer than the number of patients on the transplant list. For this reason, left ventricular assist devices (LVADs), a class of electromechanical devices used for cardiac circulatory support, are increasingly being used to bridge patients to OHT. The optimal timing of when patients with LVADs should be bridged to OHT is an important consideration for patient care and has yet to be characterized.
Research frontiers
As the rate of LVAD implantation in the United States continues to increase, effective recommendations on the in-hospital management of LVAD implantation are needed. The optimal timing of when to bridge patients with LVADs to OHT remains controversial and is an active area of research.
Innovations and breakthroughs
Few groups have studied the impact of timing of same-admission OHT after LVAD on patient outcomes. Past studies on the appropriate use and outcomes of LVADs have been mostly limited to institutional experience and case series of select populations. The authors used the Nationwide Inpatient Sample (NIS), the largest national database of hospitalizations in the United States with data from over 36 million hospitalizations, to assess the optimal timing of OHT after LVAD implantation. It has been suggested that performing OHT early after LVAD placement confers an increased risk to patient. The study corroborates these claims and concludes that early OHT after LVAD placement (less than 8 d) is associated with increased in-hospital mortality. Therefore, depending on the clinical scenario, it might be reasonable for physicians to defer OHT immediately after LVAD placement.
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